Background: Administrative data are frequently used to identify venous thromboembolism (VTE) for research and quality reporting. However, the validity of these codes, particularly in outpatients, has not been well-established.
BACKGROUND
Venous thromboembolism (VTE) is a major public health problem in the United States, affecting an estimated 300,000-600,000 people nationally each year. [1] [2] [3] Because of the significant morbidity and mortality resulting from pulmonary embolism (PE) and deep venous thrombosis (DVT), VTE has become a target for active surveillance and quality reporting. 2, [4] [5] [6] Governmental and regulatory agencies such as the Agency for Healthcare Research and Quality, the Joint Commission, and the Centers for Medicare & Medicaid Services have adopted measures of VTE to assess hospital quality. 7, 8 Identifying VTE events for the purposes of quality reporting and research relies heavily on the use of administrative codes, primarily using International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes. 1, 5, 9 However, the validity of using ICD-9 codes to identify VTE events remains questionable. 5 Although some studies have found that ICD-9 codes are reasonably concordant with medical chart review, others have found much lower rates of validity, and rates that vary by the type and position of the code. 5, [10] [11] [12] [13] Moreover, most studies addressing the validity of VTE ICD-9 codes have been conducted only in hospital or postoperative settings and in earlier treatment eras. As the diagnosis and management of VTE moves increasingly to the outpatient arena, it is vital to determine whether outpatient VTE codes are reliable proxies for true clinical events before these diagnostic codes can be depended on for research, policy, and quality reporting purposes. The objective of our multicenter study was to examine the validity of VTE ICD-9 diagnosis codes in both inpatient and outpatient settings based on medical chart review.
PATIENTS AND METHODS

Identification of Potential VTE Events
We obtained clinical and administrative data from 4 integrated health care delivery systems that participated in the Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) study. The 4 systems represented diverse geographic health plan members from: Kaiser Permanente Northern California, which during the study period served >3.2 million members in Northern California; Kaiser Permanente Colorado, which served >460,000 members in the Denver, Colorado metropolitan area; Marshfield Clinic, which served >550,000 members in central and northwest Wisconsin; and Geisinger Health System, which served approximately 2.5 million members in central and northwest Pennsylvania.
We included adult health plan members (aged 21 y and above) who were enrolled for at least 12 months and with continuous pharmacy benefits, who had a least 1 clinical encounter with a diagnosis code for VTE during the time period October 1, 2004 through December 31, 2010. The index VTE event was defined as the first encounter associated with a VTE diagnosis code during the study time period. To focus on incident VTE events, we excluded patients with a prior diagnostic code for VTE while enrolled in the health plan, or who were prescribed relevant anticoagulants, within 4 years of the index event.
VTE 8, 453.89, 453.9) . Codes for pregnancy-related VTE and superficial thrombophlebitis were not included in this study. All encounters with a VTE diagnosis were included in the search, including from hospital, emergency department (ED), and outpatient settings.
Validation of VTE Events
Of the 42,941 individuals with an index VTE encounter, 5264 were selected for manual medical record review. For 2 of the sites, all available charts with a VTE encounter were reviewed. For the other 2 sites, a random sample of the charts were selected for review due to the large number of potential events. Electronic medical record systems were available at all clinical sites during the time period of the study. Research staff obtained all available hospital admission, transfer, and discharge notes, as well as ED notes, outpatient encounter notes, and relevant radiology reports within 72 hours before and after the VTE encounter date. Records were then reviewed by trained physician and pharmacist reviewers who used a structured data abstraction tool to determine whether encounters represented valid, acute VTE events. An event was considered to be valid if there was radiologic, operative, or autopsy evidence of acute VTE, or if a physician documented in the medical record that an acute VTE occurred during that episode of care. VTE events whose acute management was not contiguous with the current episode (such as patients with a history of previously treated VTE) were not considered valid events. Superficial venous thrombophlebitis was not considered to be a valid VTE.
If a reviewer determined that the encounter did not represent a valid, acute VTE, he/she then categorized the event as one of the following: past history of VTE but not an acute event, superficial venous thrombophlebitis, non-VTE alternative diagnosis, "rule-out VTE" (where VTE was suspected but the diagnostic test was negative), or insufficient information in the medical documentation to confirm an acute VTE event.
Subject Characteristics
Characteristics of the subjects were obtained from clinical and administrative databases, including demographic features (age, sex, race, and ethnicity) and coexisting medical conditions identified by the presence of relevant ICD-9 diagnosis codes up to 4 years before the index VTE event. Anticoagulant use was ascertained by searching health plan pharmacy databases for filled outpatient prescriptions for anticoagulants within 7 days of the VTE encounter. Anticoagulants were categorized as oral (warfarin sodium) or parenteral (low-molecular-weight heparins and fondaparinux). During the time period of the study, the target-specific oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban were not yet approved by the US Food and Drug Administration for use in acute VTE and so were not included.
Statistical Analysis
All analyses were conducted using SAS statistical software version 9.1 (Cary, NC). We reported the positive predictive value (PPV) of specific VTE codes compared with medical record review. PPV was calculated as the number of valid VTE events divided by the total number of patients within a set of VTE diagnosis codes. Subjects whose clinical documentation was unavailable for chart review were excluded from the analysis. We examined whether PPV varied according to VTE type (ie, PE, lower extremity DVT, upper extremity DVT, and other venous thrombosis), clinical setting (hospital/ED vs. outpatient), and, for hospital/ED encounters, by position of the code (primary vs. secondary). We did not distinguish between primary or secondary code positions for outpatient encounters, as outpatient visits frequently do not have a single, leading diagnosis. We then tested whether the PPV of diagnosis codes changed when we included a criterion of a filled prescription for anticoagulant within 7 days of the VTE encounter. Finally, we tested whether there were changes in PPV after October 9, 2009, when additional VTE codes became available to further specify superficial venous thrombophlebitis, chronic VTE, and upper extremity VTE. 14 This study was approved by the institutional review boards of the participating institutions and waiver of informed consent was obtained due to the nature of the study.
RESULTS
We reviewed the medical charts of 5264 subjects who had an encounter with a VTE diagnosis code during the study time period and who met the study eligibility criteria. Clinical characteristics of these individuals are presented in Table 1 . A total of 622 encounters lacked clinical documentation related to the VTE episode and were excluded from the analysis. The final analytic cohort therefore comprised 4642 individual patient encounters, of which 2890 were hospital/ED encounters and 1752 outpatient encounters.
PPV of VTE Codes
The overall PPV of any VTE code, inpatient or outpatient, was 51.9% and varied widely by clinical setting and VTE type (Table 2) . Primary discharge diagnosis codes for PE, and to a lesser degree, lower extremity DVT, obtained from a hospital/ED encounter had reasonably high PPVs (89.1% and 74.9%, respectively). Outpatient codes on the other hand were unlikely to represent acute VTE; the highest PPV in outpatients was for lower extremity DVT, which reflected chart-confirmed events only 53.6% of the time (Table 2) .
When we restricted the analysis to the 1974 patients who had an anticoagulant prescription within 7 days after being discharged from the VTE encounter, the PPV for VTE increased for both inpatients and outpatients (87.6% and When we examined the PPV of individual diagnosis codes, several codes were especially poor predictors of acute VTE (Table 4 ). In particular, codes denoting phlebitis or thrombophlebitis, even of specified deep veins, had low PPVs, as did codes for "other venous thrombosis" (Table 4) . When we compared the PPV of VTE codes pre-October 2009 and post-October 2009, the largest change was seen in the predictive value of hospital/ED diagnostic codes for upper extremity DVT, where the PPV of a primary diagnosis code of upper extremity DVT increased from 31.3% to 86.7%, and from 18.3% to 56.7% for a codes in a secondary position.
Reasons Encounters With VTE Codes Were Not Considered Valid VTE Events
There were 2606 encounters that after review were not considered valid VTE events. The reasons for being coded as invalid varied widely by setting and VTE type (Table 5) . For hospital/ED encounters, alternative non-VTE diagnoses were the most common reasons for not being considered valid. In outpatient encounters, codes for PE or lower extremity DVT often reflected a past history of VTE. Patients with an upper extremity DVT code were frequently determined to have superficial venous thrombophlebitis after chart review (Table 5) . 
DISCUSSION
Our study found that ICD-9 codes for PE in a primary position during a hospital or ED encounter accurately reflected acute VTE nearly 90% of the time when compared with chart review. However, codes for other types of VTE, and codes that were in the secondary position or from an outpatient encounter, were much less likely to represent acute VTE.
The validity of VTE ICD-9 codes increased when we added the criteria of an anticoagulant prescription dispensed shortly after discharge, and linking the presence of an ICD-9 code for VTE with an anticoagulant prescription may be 1 way to increase the likelihood that an event reflects a true acute VTE. The downside, however, of restricting to patients who received anticoagulants would be to inappropriately exclude approximately 30% of patients with valid VTE events who did not fill a prescription for anticoagulants within a week.
There was substantial variation in how well individual ICD-9 codes correlated with chart-confirmed VTE events. ICD-9 codes that were for phlebitis or thrombophlebitis (even of deep veins) or referred to unspecified or "other" locations, were in general poorly predictive of true VTE events. Although ICD-9 codes for phlebitis and thrombophlebitis have been used in prior studies of VTE and have also been adopted for quality reporting purposes, the results of our study argue that these codes are unlikely to represent true VTE events.
Our findings have significant implications for research and policies that rely on administrative codes for VTE. 6 Studies that use both inpatient and outpatient codes to identify VTE may be substantially overestimating the actual burden of disease. 15, 16 More parsimonious sets of codes, validation by chart review, or incorporating additional criteria, such as anticoagulant prescription, may help to improve the accuracy of using administrative data to identify actual VTE events. In 2007, Centers for Medicare & Medicaid Services introduced present-on-admission (POA) indicator codes to help distinguish hospital-acquired events from preexisting conditions. The use of POA codes appeared to improve identification of incident hospital-acquired VTE, but these codes were not always accurately applied. 17 In addition, POA codes are applicable only for acute hospitalizations and thus do not apply to outpatients, where the greatest need for accurate codes exists. Our study had several limitations. Some codes were infrequently observed in our sample, including codes for venous thrombosis in unusual sites like the renal vein. We were unable to review the medical charts of 622 patients, and because unavailable medical charts were more often for outpatient encounters, it is possible that a review of these charts would have increased our estimated PPV for outpatient VTE from its very low level of 30.9%. However, we note that even if all missing charts were considered to be valid VTE events, the predictive value of outpatient codes would not be high enough for policy and research applications. Finally, an expanded set of VTE codes was introduced in October 2009, most notably to help delineate chronic from acute VTE and superficial from DVT. Although we found some modest effects, others have reported much higher PPVs associated with the use of these codes. 14 As these codes were only available for slightly >1 year of our study period, it is possible that accuracy of inpatient VTE codes has improved even more since then.
Administrative databases are increasingly used for outcomes research and quality measurement in VTE. It is important to acknowledge the limitations of using such databases. Outpatient VTE codes, in particular, should not currently be relied upon to provide accurate representations of acute VTE and additional ways to confirm VTE events in outpatients are needed. 
